Home/ Stocks/ KALV

KalVista Pharmaceuticals, Inc. Common Stock

KALV XNAS

$16.46 -0.14 (-0.84%) ▼ 15-min delayed

Open

$16.47

High

$16.57

Low

$15.95

Volume

698.3K

Market Cap

$839.07M

About KalVista Pharmaceuticals, Inc. Common Stock

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 270 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$13.70M	$-49,482,000	$-0.92
Q1 2026	$1.40M	$-60,096,000	$-1.12
FY 2025	$0	$-183,444,000	$-3.69
Q2 2025	$0	$-42,268,000	$-0.91

Related Market News

No specific coverage for KALV yet. Check out our latest market news or earnings calendar.

Get KALV Alerts

Stay ahead with breaking news, price alerts, and expert analysis on KalVista Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.